Pipeline
Addressing life-threatening, difficult-to-treat solid tumors
A2 Bio’s Pipeline
Our rich pipeline includes four pre-clinical programs with different clinically validated solid tumor targets. Tmod™ technology is modular, flexible and compatible with many types of immune cells, as well as manufacturing platforms. A2 Bio is focusing on the use of T cells for our initial pipeline.
Our pipeline
Our pipeline
AUTOLOGOUS
PROGRAM
A2B530
ACTIVATOR
CEA
BLOCKER
HLA-A*02
INDICATION
Colorectal, Lung, and Pancreatic Cancers
Target IND Submission
H2 2022
Commercial Rights
Discovery
IND-Enabling
Phase1
Phase2
AUTOLOGOUS
PROGRAM
A2B694
ACTIVATOR
MSLN
BLOCKER
HLA-A*02
INDICATION
Ovarian, Mesothelioma, Colorectal, Lung and Pancreatic Cancers
Target IND Submission
H1 2023
Commercial Rights
Discovery
IND-Enabling
Phase1
Phase2
ALLOGENEIC
PROGRAM
Undisclosed
ACTIVATOR
Undisclosed
BLOCKER
Undisclosed
INDICATION
Undisclosed
Target IND Submission
H1 2024
Commercial Rights
Discovery
IND-Enabling
Phase1
Phase2
ALLOGENEIC
PROGRAM
Undisclosed
ACTIVATOR
Undisclosed
BLOCKER
Undisclosed
INDICATION
Undisclosed
Target IND Submission
H2 2024
Commercial Rights
Discovery
IND-Enabling
Phase1
Phase2
Programs
Our two lead programs are autologous, followed by two allogeneic candidates. The Tmod™ platform is modular, enabling vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations.
Watch how Tmod™ T cells selectively kill tumor cells while sparing normal cells
A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity on normal tissues.
Clinical trials
BASECAMP-1
BASECAMP-1 is a pre-screening protocol to identify potential eligible patients for our future trials. The objective of BASECAMP-1 is to use next-generation sequencing to collect information on solid tumor loss of human leukocyte antigen (HLA) and perform leukapheresis to collect and store eligible participants’ own T cells for future use to potentially make a CAR T cell therapy for their disease treatment. For more information and participating cell therapy sites of excellence, visit BASECAMP-1 (NCT04981119).